Alternative Models Of Differential Pricing For Medicines
Tomas J. Philipson, Senior Economic Advisor to the Administrator, Centers for Medicare & Medicaid Services ; David Meeker, President, LSD Therapeutics, Genzyme Corporation; Una Ryan, President & CEO, AVANT Immunotherapeutics, Inc.; Patricia M. Danzon, Chair, Health Care Systems Department Celia Z. Moh Professor Professor of Health Care Systems and Insurance and Risk Management The Wharton School of Management, University of Pennsylvania; Hannah E. Kettler, Program Officer, Global Health Strategies; The Bill & Melinda Gates Foundation ;
Description: Each speaker on this panel proposes a unique approach to the problem of making medicines universally affordable. Dr. David Meeker works in the area of rare diseases. Genzyme's hormone replacement therapy for Gaucher disease, which affects roughly 30 thousand globally, costs $150k to $200k per year. For patients in nations with poor health care systems, Genzyme discounts the medicine steeply. "Don't say free drugs," says Meeker. "We'll help individual patients as best we can but we're going to work on developing a health care system in that country that will eventually be able to take over." At Avant Immunotherapeutics, Una Ryan's company tackles new vaccines for travelers, bio-defense, global health and food safety uses. "We're trying to making vaccines people will actually take: safe, effective, oral, single dose, rapid protection and no refrigeration." There are enormous development costs involved, which are hard for a small company to shoulder, she says. Perhaps "all developed nations should pay their fair share for pharma R&D 'and for developing countries' drugs," indexing drug prices to each nation's GDP. Patricia Danzon suggests that drug manufacturers sell "products to wholesalers at uniform prices worldwide, then negotiate confidential rebates with final purchasers... This way, the lower prices offered to lower income countries won't spill over to higher income countries." Hannah Kettler describes the Gates Foundation's efforts to invest funds in public-private partnerships to reduce pharmaceutical RD costs. The foundation is also trying to build a fund to cover the costs of vaccinating in developing countries. Our expectation, she says, "is that if we pay the higher prices now, supply will expand and over time the price of vaccines will come down."
Host(s): Sloan School of Management, MIT Sloan School of Management
It looks like no one has posted a comment yet. You can be the first!
More from MIT World — special events and lectures
Added over 3 years ago | 01:33:00 | 2342 views
Added over 3 years ago | 00:58:29 | 1870 views
Added over 3 years ago | 01:15:00 | 3069 views
Added over 3 years ago | 01:24:00 | 1892 views
Added over 3 years ago | 01:39:00 | 2971 views
Added over 3 years ago | 01:03:00 | 3630 views